omecamtiv mecarbil
AssetAlso CK-1827452
Activates cardiac myosin to increase cardiac contractility and improve systolic function.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- MYH7
- 2
- Indications
- 1
- Trial
- 1
- Developer
Indications
2Heart failure
Phase 3, Recruiting, NCT06736574, clinicaltrials.gov, 16 Oct 2026
Heart failure with reduced ejection fraction
Phase 3, Recruiting, NCT06736574, clinicaltrials.gov, 16 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Competitors12
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.